Adi Mohanty
Vorstandsvorsitzender bei BIORA THERAPEUTICS, INC.
Vermögen: 97 752 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Brian Culley | M | 53 | 6 Jahre | |
| Eric d'Esparbes | M | 56 | 5 Jahre | |
| Jeffrey Alter | M | 61 | 5 Jahre | |
| Robert W. Peabody | M | 69 |
Cell Cure Neurosciences Ltd.
 Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | 9 Jahre |
| David Schlachet | M | 78 |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | 5 Jahre |
| Andy Arno | M | 64 | 9 Jahre | |
| Brian Kotzin | M | 74 | 5 Jahre | |
| Padma Sundar | F | - | 5 Jahre | |
| Jill Howe | F | 48 | 3 Jahre | |
| Lynne Powell | F | 57 | 5 Jahre | |
| Andrew Last | M | 64 | 9 Jahre | |
| Jeffrey Allen Ferrell | M | 49 | 10 Jahre | |
| Clarke Neumann | M | 60 | 10 Jahre | |
| Allison Luo | M | 50 | 7 Jahre | |
| Robyn Hatton | F | - | 11 Jahre | |
| Michael Rhode | M | - | - | |
| Francine Del Ricci | F | - |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | - |
| Gary S. Hogge | M | 56 | 6 Jahre | |
| Michael D. West | M | - |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | 22 Jahre |
| Frank Lanza | M | 62 | 8 Jahre | |
| Leslie Waltke | F | - | 12 Jahre | |
| Paul W. Shabram | M | - | 2 Jahre | |
| Raf Hofstein | M | 74 |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | - |
| Benjamin Reubinoff | M | - |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | 18 Jahre |
| Rami Skaliter | M | 66 |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | 7 Jahre |
| Sharat Singh | M | - | - | |
| Ariella Kelman | M | - | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Cavan Redmond | M | 63 | 7 Jahre | |
| Russell Skibsted | M | 65 | 4 Jahre | |
| Ronald Andrews | M | 64 | 4 Jahre | |
| Steve Cartt | M | 61 | 5 Jahre | |
| Graham Hetherington | M | 65 | 6 Jahre | |
| Don Bailey | M | 78 | 3 Jahre | |
| James Bowling | M | 56 | 10 Jahre | |
| Pedro Lichtinger | M | 70 | 2 Jahre | |
| Ryan D. Chavez | M | 48 | 3 Jahre | |
| Michael Mulroy | M | 58 | 2 Jahre | |
| Susan Kilsby | F | 65 | 8 Jahre | |
| Angus Russell | M | 68 | 14 Jahre | |
| Michael West | M | 71 | 16 Jahre | |
| William Annett | M | 70 | 4 Jahre | |
| Stephana Patton | M | 54 | 2 Jahre | |
| William Haack | M | - | 2 Jahre | |
| Dominic Blakemore | M | 54 | 4 Jahre | |
| Ian Karp | M | - | 5 Jahre | |
| William Ciambrone | M | 60 |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | 9 Jahre |
| Ludovic Robin | M | - | 8 Jahre | |
| Melinda Griffith | F | 69 | - | |
| Albert Parker | M | 58 | 2 Jahre | |
| Tony Kalajian | M | 54 | 4 Jahre | |
| Surbhi Sarna | F | 38 | 2 Jahre | |
| David R. Ginsburg | M | 71 | 8 Jahre | |
| Flemming Ørnskov | M | 66 | 6 Jahre | |
| Doug Treco Treco | M | 66 |
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 17 Jahre |
| Tamara Joseph | F | 61 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 1 Jahre |
| William Burns | M | 76 | 8 Jahre | |
| Howard I. Scher | M | 72 | 3 Jahre | |
| Steven Gillis | M | 71 | 7 Jahre | |
| Anne Minto | F | 70 | 8 Jahre | |
| Mitchell Levine | M | - | - | |
| David Stout | M | 69 | 6 Jahre | |
| Iain Ward | M | - | 8 Jahre | |
| Roger Adsett | M | 55 | 11 Jahre | |
| Jonathan Leff | M | 55 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 5 Jahre |
| Thomas P. Mcdonnell | M | 52 | 2 Jahre | |
| Kristine C. Mechem | M | - | 4 Jahre | |
| Jill Quigley | F | 49 | 4 Jahre | |
| Daniel Geffken | M | 67 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 6 Jahre |
| Paul Streck | M | 60 | 2 Jahre | |
| Joanne Cordeiro | F | 66 | 8 Jahre | |
| Daryl DeKarske | M | - | 7 Jahre | |
| Konstantinos Andrikopoulos | M | 58 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 3 Jahre |
| Michael Heartlein | M | 65 |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | 13 Jahre |
| Neil Kirby | M | 63 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | - |
| Debra Silberg | M | - | - | |
| Andrew Komjathy | M | 61 |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | 7 Jahre |
| Daniel Dolan | M | 47 | 12 Jahre | |
| Perry Sternberg | M | 55 | 6 Jahre | |
| Joff Masukawa | M | - | - | |
| Jane S. Lebkowski | M | 68 | 4 Jahre | |
| Simon Gibbins | M | 58 | 9 Jahre | |
| Timothy Kelly | M | 55 | 8 Jahre | |
| Mark Enyedy | M | 60 | 3 Jahre | |
| David MacKney | M | 56 | 3 Jahre | |
| Michael G. Vicari | M | - | 1 Jahre | |
| Anthony S. Murabito | M | - |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 2 Jahre |
| Deanna M. Petersen | F | 62 | 6 Jahre | |
| Lyssa Friedman | F | - | 4 Jahre | |
| Gregory Perry | M | 63 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 2 Jahre |
| David Colpman | M | 62 | 15 Jahre | |
| Brooke Clarke | F | - | 5 Jahre | |
| Charlotte Sibley | F | 77 | 5 Jahre | |
| Mario David Saltarelli | M | 63 | 2 Jahre | |
| Barbara H. Deptula | F | 69 | 8 Jahre | |
| Obed M. Cepeda | M | - |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 1 Jahre |
| Raymond Pratt | M | 73 | 7 Jahre | |
| Sylvia Cheung | F | 50 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 5 Jahre |
| Georgia Erbez | F | 57 | 1 Jahre | |
| Barry James Price | M | 80 | 14 Jahre | |
| Miguel Coego Rios | M | - | 8 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 57 | 57,00% |
| Irland | 39 | 39,00% |
| Israel | 7 | 7,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Adi Mohanty
- Persönliches Netzwerk
